53 results about "Antimitotic Agent" patented technology

The invention discloses and claims benzimidazole compounds of formula (I):

wherein X is C—R2; Y is C—R2 or C—R3; W and Z are each C—R3; R1 is an optionally substituted aryl, heteroaryl or a saturated 5- or 6-membered monocyclic heterocyclic radical or a bicyclic heterocyclic radical; and A5 is H or alkyl; or a stereoisomer, a racemate, an enantiomer or a diastereoisomer of said compound of formula (I) or a pharmaceutically acceptable salt thereof; the use of compounds of formula (I) for the treatment of a disorder of proliferation of blood vessels, uncontrolled angiogenesis, a fibrotic disorder, a disorder of proliferation of mesangial cells, a metabolic disorder, allergy, asthma, thrombosis, a disease of the nervous system, retinopathy, psoriasis, rheumatoid arthritis, diabetes, muscle degeneration, solid tumors and cancers, pharmaceutical compositions comprising a compound of formula (I) and one or more pharmaceutically acceptable adjuvants or diluents and pharmaceutical compositions comprising a compound of formula (I) and one or more. antimitiotic agents.

The invention provides generally a method of monitoring, diagnosing, prognosing and treating glioma. Specifically, the invention provides for three (3) prognostic subclasses of glioma, which are differentially associated with activation of the akt and notch signaling pathways. Tumor displaying neural or proneural PN lineage markers (including notch pathway elements) show longer median patient survival, while the two remaining tumor markers Prolif and Mes are associated with shortened survival. Tumors classified in this manner may also be treated with the appropriate PN- Prolif- or Mes-therapeutic corresponding to the subclassification in combination with anti-mitotic agents, anti-angiogenic agents, Akt antagonists, and neural differentiation agents. Alternatively, the invention also provides for method of prognosing and diagnosing glioma with a two-gene model based on the expression levels of PTEN and DLL3.

The invention discloses embossed texture decorative mortar which is dry-mixed mortar prepared by mechanically stirring cement, sand, auxiliary materials, emulsion powder, cellulose ether, an antimitotic agent, an expanding agent and other functional auxiliaries according to a certain proportion. The embossed texture decorative mortar prepared by the invention has the characteristics such as high strength after being hardened, good toughness, impact resistance, durability and roller coating property, elegant decorative effect, high texture and the like so as to be suitable for forming various three-dimensional concave-convex decorative effects.

The invention relates to an extra-light porous thermal insulating material and a method for preparing the same. The extra-light porous thermal insulating material is prepared from the following components by mass percent through mixing: 65-80% of cement, 5-25% of metakaolin, 5-15% of micro-silica, 3-6% of foamer, 0.5-2% of foam stabilizer, 0.2-0.6% of antimitotic agent and 0.5-2% of excitant. The method for preparing the extra-light porous thermal insulating material comprises the steps of: pretreating the cement, preparing the metakaolin, preparing the foam stabilizer, preparing the antimitotic agent, preparing the excitant and preparing the thermal insulating material. The method provided by the invention is significant in improving the thermal insulation property, fireproofing property, safety and durability of a building; and simultaneously, the provided thermal insulating material has the advantages of low dry density, low coefficient of heat conductivity and high strength.

The application discloses novel synthetic compounds, modeled after unique toxins extracted from the marine invertebrate Diazona angulata useful in the treatment abnormal cell mitosis. The application also discloses novel methods for synthesis of these compounds and methods of using these compounds.

Tubulysin compounds of the formula (I)

where R¹, R²R^3a, R^3b, R⁴, R⁵, W, and n are as defined herein, are anti-mitotic agents that can be used in the treatment of cancer, especially when conjugated to a targeting moiety.

The invention discloses an anti-cracking sulphate aluminium cement plant fiber product, being prepared from the following component raw materials in parts by weight: sulphate aluminium cement, bits of wood, silica fume, coal ash, glass fiber, water, retarder, water-retaining agent, thickener and antimitotic agent. The preparing method comprises: (1) weighing the respective component raw materials in parts by weight; (2) adding the sulphate aluminium cement, bits of wood, silica fume, coal ash and glass fiber in to water and stirring, adding the water-retaining agent, thickener and antimitotic agent and stirring, standing; (3) adding the retarder, stirring, conveying into a roller level production workshop, entering a template, filling, performing roller leveling to produce a wet panel, cutting, and then conveying into a curing workshop for curing. The product has a smooth surface, no cracks, no cracking phenomenon, high strength and high durability; further, the product has easily obtained raw materials and low cost and the preparing method is low in cost and easy and simple to operate.

A method of treating a neoplastic disease in a subject includes administering to neoplastic cells of the subject an MGMT inhibitor and at least one of an antimitotic agent or a DNA damaging agent.

The invention relates to an additive for spraying plastering mortar. The additive is prepared from the following raw materials in parts by weight: 50-65 parts of a thickening thickener, 2-8 parts of an air entraining agent, 15-40 parts of a strength excitant, 2-10 parts of a thickening time control agent and 20-45 parts of an expansive antimitotic agent, wherein the thickening thickener is selected from one or more of polyacrylamide, redispersible powder, polyvinyl alcohol, hydroxymethyl cellulose ether, carboxymethylcellulose ether and the like; and the air entraining agent is selected from one or more of sodium dodecyl sulfate, sodium abietate and triterpenoid saponin. According to the additive provided by the invention, the mortar has sprayability and can be firmly attached to the wall space and is not sticky to a cutter, so that leveling construction is facilitated.

Methods and compositions are provided to determine if a cancer is resistant to treatment with anti-mitotic agents, including treatment with T-DM1. The methods relate to determining if the ABCC3 gene is amplified and/or overexpressed in the cancer.

The present invention relates to a method for treating solid cancers including non-small 5 cell lung cancer, pancreatic, bladder, breast and ovarian cancer as well as advanced biliary tract cancers comprising administering at least one antineoplasticagent such as a nucleotide analog, for example gemcitabine, or an antimitotic such as docetaxel, in combination with a tyrosine kinase inhibitor selected from 2-aminoarylthiazoles and 2-aminoaryloxazoles.

The present invention provides targeted polymeric nano-complexes for delivery of drugs such as anti-mitotic agents or anti-cancer agents. The present invention also provides a process for the preparation of such targeted nano-complexes.